The Use of Monoclonal Antibodies in the Treatment of Alzheimer Disease

Authors

  • Hemen Moradi-Sardareh Department of Clinical Biochemistry, Medical School, Tehran University of Medical Sciences, Tehran, Iran.
  • Maryam Moradi Department of Immunology and Hematology, Faculty of Medicine, Kurdistan University Of Medical Sciences, Sanandaj, Iran.
  • Elham Bordbar Departments of Sciences, Faculty of Biochemistry, East Tehran Branch, Payame Noor University (PNU), Tehran, Iran.
  • Mohammadreza Malekpour Department of Medical Nanotechnology, School of Advanced Technologies In Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Sara Bagheri Department of Clinical Biochemistry, Medical School, Hamadan University of Medical Sciences, Hamadan, Iran.
  • Nasrin Nakhodazadeh In One of Laboratory Located on Southeast At Tehran Town.
  • Shahin Rahbar Institute of Medical History Studies, Islamic And Complementary Medicine, Iran University of Medical Sciences.
  • Javad Farhadian Asgarabadi Expert of Public Health, Shahroud University of Medical Sciences, Iran.

DOI:

https://doi.org/10.31557/apjcb.2016.1.3.59-66

Keywords:

Alzheimer disease- antibody- Crenezumab- Solanezumab

Abstract

Background and objective: Antibody molecules have similar structure but variable binding sites to antigen. Human antibodies are achieved by transgenic mouse technology or phage display. Antibodies are used for the treatment of different diseases. Alzheimer is a cow disease with a delayed onset overpresenting in adults in their 70s to 90s. This disease is the leading cause of central nervous system (CNS) degeneration during 7 to 15 years in the aging population. Several hypotheses have offered monoclonal antibodies action mechanism in relation to amyloid cleaning at Alzheimer disease. According to this mechanism, the appropriate antibody passes blood-brain barrier, enters into brain, and binds to amyloid to launch its phagocytosis activity in microglia and/or macrophage/monocytes infiltrating. The present study aimed to review antibody structure and the use of different antibodies for the treatment of Alzheimer disease.

Downloads

Published

2016-09-25

How to Cite

1.
Moradi-Sardareh H, Moradi M, Bordbar E, Malekpour M, Bagheri S, Nakhodazadeh N, et al. The Use of Monoclonal Antibodies in the Treatment of Alzheimer Disease. Asian Pac J Cancer Biol [Internet]. 2016 Sep. 25 [cited 2026 Jun. 8];1(3):59-66. Available from: http://waocp.com/journal/index.php/apjcb/article/view/200

Issue

Vol. 1 No. 3 (2016)

Section

Research Articles/ Original Work

License

 West Asia Organization for Cabcer Prevention retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4 (This permits anyone to copy, distribute, transmit and adapt the published work, provided the original work and source are appropriately cited).